OncoMatch/Clinical Trials/NCT07787429
Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma
Is NCT07787429 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Mifamurtide and Sorafenib for osteosarcoma.
Treatment: Mifamurtide · Sorafenib — Prospective, open, interventional, randomized, non-commercial trial
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Osteosarcoma
Demographics
Prior therapy
Cannot have received: mifamurtide (mifamurtide)
Previous treatment with mifamurtide
Lab requirements
Cardiac function
Significant cardiac conduction abnormalities, including a known family history of long QT syndrome or a corrected QT interval (QTc) > 480 ms; symptoms of congestive heart failure or a left ventricular ejection fraction < 50%
Significant cardiac conduction abnormalities, including a known family history of long QT syndrome or a corrected QT interval (QTc) > 480 ms. Symptoms of congestive heart failure or a left ventricular ejection fraction < 50%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07787429 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior mifamurtide disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 30 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages